Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVADE: ADG20 for Prevention of COVID-19
NCT04859517Phase 3Terminated
- Sponsor
- Invivyd
- Start
- Apr 2021
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of adintrevimab in coronavirus disease 2019 (COVID-19), sponsored by Invivyd. Started Apr 2021; status: terminated.
02
Drugs
adintrevimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04859517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04859517.